Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (3): 231-236.doi: 10.11958/20230719
• Cell and Molecular Biology • Previous Articles Next Articles
MAN Jun1(), GAO Yanyan1, SONG Longfei2, GAO Fusheng1,△(
)
Received:
2023-05-19
Revised:
2023-08-12
Published:
2024-03-15
Online:
2024-03-13
Contact:
△E-mail: MAN Jun, GAO Yanyan, SONG Longfei, GAO Fusheng. The effect of lncRNA FEZF1-AS1 targeting regulation of miR-200c-3p on biological behaviors of human lung fibroblasts[J]. Tianjin Medical Journal, 2024, 52(3): 231-236.
CLC Number:
基因名称 | 引物序列(5'→3') | 产物大小/bp |
---|---|---|
LncRNA FEZF1-AS1 | 上游:TTAGGAGGCTTGTTCTGTGT | 239 |
下游:GCGCAGGTACTTAAGAAAGA | ||
miR-200c-3p | 上游:UAAUACUGCCGGGUAAUGAUGGA | 70 |
下游:UCCAUCAUUACCCGGCAGUAUUA | ||
GAPDH | 上游:GCCTTCCGTGTCCCCACTGC | 216 |
下游:GGCTGGTGGTCCAGGGGTCT | ||
U6 | 上游:CTCGCTTCGGCAGCACA | 65 |
下游:AACGCTTCACGAATTTGCGT |
Tab.1 Primer sequence
基因名称 | 引物序列(5'→3') | 产物大小/bp |
---|---|---|
LncRNA FEZF1-AS1 | 上游:TTAGGAGGCTTGTTCTGTGT | 239 |
下游:GCGCAGGTACTTAAGAAAGA | ||
miR-200c-3p | 上游:UAAUACUGCCGGGUAAUGAUGGA | 70 |
下游:UCCAUCAUUACCCGGCAGUAUUA | ||
GAPDH | 上游:GCCTTCCGTGTCCCCACTGC | 216 |
下游:GGCTGGTGGTCCAGGGGTCT | ||
U6 | 上游:CTCGCTTCGGCAGCACA | 65 |
下游:AACGCTTCACGAATTTGCGT |
组别 | α-SMA | Collagen Ⅰ | Vimentin |
---|---|---|---|
Blank组 | 0.68±0.02 | 0.37±0.05 | 0.66±0.06 |
HLF+TGF-β1组 | 0.90±0.02 | 0.68±0.05 | 0.98±0.04 |
t | 7.621* | 7.431* | 4.583* |
Tab.2 Comparison of α-SMA, Collagen Ⅰ and Vimentin protein expressions between two groups of cells
组别 | α-SMA | Collagen Ⅰ | Vimentin |
---|---|---|---|
Blank组 | 0.68±0.02 | 0.37±0.05 | 0.66±0.06 |
HLF+TGF-β1组 | 0.90±0.02 | 0.68±0.05 | 0.98±0.04 |
t | 7.621* | 7.431* | 4.583* |
组别 | 0 h | 24 h | 48 h | F |
---|---|---|---|---|
Blank组 | 0.49±0.00 | 0.65±0.01A | 1.08±0.02AB | 640.000* |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.48±0.01 | 1.08±0.03aA | 1.87±0.03aAB | 641.500* |
TGF-β1+Si LncRNA FEZF1-AS1组 | 0.47±0.02 | 0.84±0.01abA | 1.53±0.07abAB | 185.300* |
F | 0.719 | 108.400* | 79.310* |
Tab.3 Comparison of cell proliferation between three groups
组别 | 0 h | 24 h | 48 h | F |
---|---|---|---|---|
Blank组 | 0.49±0.00 | 0.65±0.01A | 1.08±0.02AB | 640.000* |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.48±0.01 | 1.08±0.03aA | 1.87±0.03aAB | 641.500* |
TGF-β1+Si LncRNA FEZF1-AS1组 | 0.47±0.02 | 0.84±0.01abA | 1.53±0.07abAB | 185.300* |
F | 0.719 | 108.400* | 79.310* |
组别 | 划痕愈合率/% | 侵袭细胞数/(个/视野) |
---|---|---|
Blank组 | 61.98±1.56 | 236.00±2.08 |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 89.16±0.78a | 413.30±16.23a |
TGF-β1+Si LncRNA FEZF1-AS1组 | 79.74±0.68ab | 329.30±25.22ab |
F | 162.500* | 26.120* |
Tab.4 Comparison of cell scratch healing rate and invasion number between three groups
组别 | 划痕愈合率/% | 侵袭细胞数/(个/视野) |
---|---|---|
Blank组 | 61.98±1.56 | 236.00±2.08 |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 89.16±0.78a | 413.30±16.23a |
TGF-β1+Si LncRNA FEZF1-AS1组 | 79.74±0.68ab | 329.30±25.22ab |
F | 162.500* | 26.120* |
组别 | α-SMA | CollagenⅠ | Vimentin |
---|---|---|---|
Blank组 | 0.57±0.01 | 0.32±0.02 | 0.33±0.01 |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.85±0.02a | 0.84±0.01a | 0.92±0.01a |
TGF-β1+Si LncRNA FEZF1-AS1 组 | 0.70±0.02ab | 0.67±0.03ab | 0.67±0.01ab |
F | 65.610* | 129.100* | 1170.000* |
Tab.5 Expressions of α-SMA, CollagenⅠ and Vimentin in each group
组别 | α-SMA | CollagenⅠ | Vimentin |
---|---|---|---|
Blank组 | 0.57±0.01 | 0.32±0.02 | 0.33±0.01 |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 0.85±0.02a | 0.84±0.01a | 0.92±0.01a |
TGF-β1+Si LncRNA FEZF1-AS1 组 | 0.70±0.02ab | 0.67±0.03ab | 0.67±0.01ab |
F | 65.610* | 129.100* | 1170.000* |
组别 | LncRNA FEZF1-AS1 | miR-200c-3p |
---|---|---|
Blank组 | 1.28±0.11 | 1.05±0.02 |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 7.53±0.14a | 0.15±0.01a |
TGF-β1+Si LncRNA FEZF1-AS1组 | 2.62±0.04ab | 0.45±0.00ab |
F | 952.100* | 1 065.000* |
Tab.6 Expressions of LncRNA FEZF1-AS1 and miR-200c-3p in each group
组别 | LncRNA FEZF1-AS1 | miR-200c-3p |
---|---|---|
Blank组 | 1.28±0.11 | 1.05±0.02 |
TGF-β1+Si LncRNA FEZF1-AS1 NC组 | 7.53±0.14a | 0.15±0.01a |
TGF-β1+Si LncRNA FEZF1-AS1组 | 2.62±0.04ab | 0.45±0.00ab |
F | 952.100* | 1 065.000* |
[1] | KATZEN J, BEERS M F. Contributions of alveolar epithelial cell quality control to pulmonary fibrosis[J]. J Clin Invest, 2020, 130(10):5088-5099. doi:10.1172/JCI139519. |
[2] | MA H B, WU X Y, LI Y, et al. Research progress in the molecular mechanisms,therapeutic targets,and drug development of idiopathic pulmonary fibrosis[J]. Front Pharmacol, 2022, 13:963054. doi:10.3389/fphar.2022.963054. |
[3] | COX I A, OTAHAL P, DE GRAAFF B, et al. Incidence,prevalence and mortality of idiopathic pulmonary fibrosis in Australia[J]. Respirology, 2022, 27(3):209-216. doi:10.1111/resp.14194. |
[4] | VANCHERI C, KREUTER M, RICHELDI L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. results of the INJOURNEY trial[J]. Am J Respir Crit Care Med, 2018, 197(3):356-363. doi:10.1164/rccm.201706-1301OC. |
[5] | BRIDGES M C, DAULAGALA A C, KOURTIDIS A. LNCcation:lncRNA localization and function[J]. J Cell Biol, 2021, 220(2):e202009045. doi:10.1083/jcb.202009045. |
[6] | ZHANG T, YU S, ZHAO S. LncRNA FEZF1-AS1 promotes colorectal cancer progression through regulating the miR-363-3p/PRRX1 pathway[J]. Adv Clin Exp Med, 2021, 30(8):839-848. doi:10.17219/acem/135693. |
[7] | PONTEMEZZO E, FOGLIO E, VERNUCCI E, et al. miR-200c-3p regulates epitelial-to-mesenchymal transition in epicardial mesothelial cells by targeting epicardial follistatin-related protein 1[J]. Int J Mol Sci, 2021, 22(9):4971. doi:10.3390/ijms22094971. |
[8] | WANG Y, LU K, LI W, et al. MiR-200c-3p aggravates gastric cell carcinoma via KLF6[J]. Genes Genomics, 2021, 43(11):1307-1316. doi:10.1007/s13258-021-01160-6. |
[9] | KURUNDKAR A R, KURUNDKAR D, RANGARAJAN S, et al. The matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury[J]. FASEB J, 2016, 30(6):2135-2150. doi:10.1096/fj.201500173. |
[10] | HERMAN A B, TSITSIPATIS D, GOROSPE M. Integrated lncRNA function upon genomic and epigenomic regulation[J]. Mol Cell, 2022, 82(12):2252-2266. doi:10.1016/j.molcel.2022.05.027. |
[11] | WANG H, WU Y, WANG Z, et al. The LncRNA FEZF1-AS1 promotes tumor proliferation in colon cancer by regulating the mitochondrial protein PCK2[J]. Oncol Res, 2022, 29(3):201-215. doi:10.32604/or.2022.03553. |
[12] | LIANG M, LI Y, DAI T, et al. lncRNA FEZF1-AS1 regulates biological behaviors of cervical cancer by targeting miRNA-1254[J]. Food Sci Nutr, 2021, 9(9):4722-4737. doi:10.1002/fsn3.2315. |
[13] | HE R, ZHANG F H, SHEN N. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC)[J]. Biomed Pharmacother, 2017, 95:331-338. doi:10.1016/j.biopha.2017.08.057. |
[14] | WANG Z H, WANG J H, WANG K Q, et al. LncRNA FEZF1-AS1 promoted chemoresistance,autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis in prostate cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(16):8250. doi:10.26355/eurrev_202008_22591. |
[15] | WANG Y D, SUN X J, YIN J J, et al. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma[J]. Biomed Pharmacother, 2018, 106:134-141. doi:10.1016/j.biopha.2018.05.116. |
[16] | MOIMAS S, SALTON F, KOSMIDER B, et al. miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation[J]. ERJ Open Res, 2019, 5(4):00138-2019. doi:10.1183/23120541.00138-2019. |
[17] | LIN S, ZHANG R, XU L, et al. LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1[J]. Cell Death Dis, 2020, 11(8):706. doi:10.1038/s41419-020-02889-w. |
[1] | YU Zhihong, WANG Xiaoqin. Effects of imperatorin derivatives on the activity and drug resistance protein of alveolar type Ⅱ epithelial cells in COPD [J]. Tianjin Medical Journal, 2024, 52(11): 1127-1130. |
[2] | LI Dongsheng, QIN Yirong, QIAO Man, CHI Hang, CUI Qingmin, LI Xiaoqiu. Clinical effects of Qingke Pingchuan Granule on acute exacerbation of COPD [J]. Tianjin Medical Journal, 2024, 52(8): 854-857. |
[3] | LI Xin, LI Xue, WANG An. Effects of chrysotile on expression of Wnt5a, p16 and p21 in endothelial cells [J]. Tianjin Medical Journal, 2024, 52(7): 679-682. |
[4] | FENG Liting, LI Li, XIE Xin, WANG Xing. Analysis of influencing factors of chronic obstructive pulmonary disease in permanent residents in some area of Tianjin [J]. Tianjin Medical Journal, 2024, 52(4): 427-431. |
[5] | LUO Cheng, ZHANG Ning, PENG Yanru, LI Shu, GUO Yali, WANG Yuguang. Analysis of the clinical characteristics and influencing factors of fatigue symptoms in patients with interstitial lung disease [J]. Tianjin Medical Journal, 2023, 51(11): 1237-1241. |
[6] | XU Nongyu, ZHONG Jiangshan, LI Duo. Protective effect and mechanism of inosine on acute lung injury induced by lipopolysaccharide in rats [J]. Tianjin Medical Journal, 2023, 51(10): 1071-1075. |
[7] | XIONG Gaocai, YANG Yuanfeng, LI Jiasong, LIU Tingqian, HE Bingbing, LIU Zhuoling. Early diagnostic value of serum miR-134-5p and miR-320a combined with pulmonary function index in coal worker pneumoconiosis patients [J]. Tianjin Medical Journal, 2023, 51(8): 860-863. |
[8] | SUN Liyan, LIU Zeru, SU Yongsheng, AI Hongliang. Effect of asperuloside on pyroptosis of lung tissue in septic rats by regulating NLRP3/Caspase-1/GSDMD signaling pathway [J]. Tianjin Medical Journal, 2023, 51(6): 607-612. |
[9] | HUANG Chengjun, XU Yu, MI Le, WANG Xiujun, LIU Zhenfeng, WANG Hongman. Research progress of autophagy in acute respiratory distress syndrome [J]. Tianjin Medical Journal, 2023, 51(6): 668-672. |
[10] | HAN Jiao, WANG Huabing, XU Lingwen, DONG Fang. The role of γ-secretase inhibitor in pulmonary fibrosis epithelial-mesenchymal transition [J]. Tianjin Medical Journal, 2022, 50(9): 917-920. |
[11] | WANG Le, CHEN Xing, LIANG Maoli, ZHANG Jing, WANG Yan, CHEN Baoyuan, CAO Jie. Analysis of influencing factors and predictive indicators of obstructive sleep apnea combined with obesity-related sleep hypoventilation [J]. Tianjin Medical Journal, 2022, 50(9): 953-958. |
[12] | SHU Xiaoyi, LI Youxia, FAN Shaohui, WANG Hongman. Research progress on the role of high mobility group protein B1 and Toll- like receptor 4 in ARDS [J]. Tianjin Medical Journal, 2022, 50(4): 433-438. |
[13] | YANG Sheng-nan, ZHAO Yong, LI Yue-chuan, JIA Wei△. The latest research progress of lymphangiomyomatosis [J]. Tianjin Medical Journal, 2020, 48(8): 790-795. |
[14] | ZHAO Tie-jun, SONG Gui-qin, ZHANG Hao-ting, CUI Wei-liang, HUANG Yong, WANG Wen-dong, ZHANG Xiao-yun. The effect of neutralizing interleukin-17 on the expressions of collagen and#br# apoptosis-related factors in model mice with idiopathic pulmonary fibrosis #br# [J]. Tianjin Medical Journal, 2020, 48(4): 258-262. |
[15] | BI Hong, JIN Zhi-xian, ZHOU Kai-hua, HE Xu, CHEN Min, WANG Qing, HUANG Zhao-ming. Advance in mechanism of vascular endothelial injury and targeted therapy in patients with overlap syndrome#br# [J]. Tianjin Medical Journal, 2017, 45(11): 1228-1232. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||